Novo Dips Into Money Pile Again To Boost Obesity Drug Manufacturing
The Danish drugmaker is investing over $4.1bn on a second facility in North Carolina for its GLP-1 therapies but has abandoned plans to build a new plant in Dublin, Ireland.
The Danish drugmaker is investing over $4.1bn on a second facility in North Carolina for its GLP-1 therapies but has abandoned plans to build a new plant in Dublin, Ireland.